|
|
Vaccine Detail
|
FRAME-001 personalized vaccine |
| Vaccine Information |
- Vaccine Name: FRAME-001 personalized vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: Frame peptides (NCT04998474)
- Immunization Route: subcutaneous injection
- Description: Tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer. (NCT04998474)
|
| Host Response |
|
|
| References |
NCT04998474: FRAME-001 Personalized Vaccine in NSCLC [https://clinicaltrials.gov/study/NCT04998474]
|
|
